Schizophrenia: Drugs, Treatments

by Food and Drug Administration (FDA)

(Page 2 of 2)

More problematic with the long-term use of older antipsychotic drugs is the development of a disorder known as tardive dyskinesia (TD), a disorder that causes involuntary movements. Patients with TD may frequently grimace, frown, smirk or experience facial tics. They may also flick or jerk their trunk, pelvis, arms, or legs. The risk of developing TD increases with the length of drug treatment and occurs in more than one-quarter of patients who have been receiving antipsychotic drugs for more than five years. In some patients, symptoms of TD may be reversed or reduced by altering the dosage of antipsychotic medication or by treating them with a different antipsychotic.

Because of the side effects, many patients do not comply with taking older antipsychotic medications. In addition, studies show these drugs don't work in a little over one-quarter of schizophrenics who do take them, according to Lisa Dixon, M.D., of the University of Maryland in Baltimore. However, three drugs have come on the market during this decade that counter some of these problems.

New Drugs

Clozapine, which can only be used to treat patients who do not respond to other antipsychotic medications, can effectively treat about one-third to one-half of those non-responders, according to UCLA's Marder.

Although it can make patients more prone to seizures, clozapine appears to cause less cramping, tremor, muscle stiffness, and restlessness than some of the older antipsychotics, and it has been suggested that clozapine may be less likely to produce TD, although the evidence on the latter is not yet definitive. However, it can make patients more prone to seizures, and about 1 to 2 percent develop a paucity of infection-fighting white blood cells. This condition, known as agranulocytosis, can be fatal if not diagnosed and treated immediately. If detected and promptly treated, however, this condition is completely reversible. To detect agranulocytosis, patients who take clozapine must have weekly blood tests.

Unlike the older antipsychotics, studies suggest clozapine, risperidone and olanzapine work by affecting the action of the neurotransmitter serotonin, as well as dopamine. Some studies suggest that in addition to effectively stemming the hallucinations and bizarre behavior of schizophrenics, these newer antipsychotic drugs can also help counter what are known as "negative symptoms," such as the social withdrawal, apathy, and paucity of emotions expressed by these patients. But as Thomas Laughren, M.D., of FDA's division of neuropharmacological drugs, notes, because the effect of older antipsychotic medications on these symptoms has not been well characterized, it is not clear whether the newer drugs have an advantage over the older ones in relieving them. "There's not sufficient evidence to conclude that risperidone or olanzapine are superior to older antipsychotics regarding negative symptoms," he said.

He added that studies with both risperidone and olanzapine suggest that they are no more likely than placebo to cause muscle stiffness, cramps, restlessness, and tremors, especially at the lower recommended doses. However, there are not sufficient data to conclude definitively that either of these newer drugs is superior to the older antipsychotic drugs in regards to these immediate side effects or the more chronic development of TD. There are a number of side effects associated with both the older and newer drugs, including sleepiness, weight gain, and sexual problems.

To minimize side effects, psychiatrists usually treat schizophrenics with the lowest dose of an antipsychotic drug that diminishes symptoms during an episode of worsening symptoms. After that episode subsides, the doctor usually will taper the dosage slowly to the lowest possible level to keep symptoms at bay. In a few circumstances, especially when symptoms are mild and patients are particularly resistant to taking medication, treatment may be discontinued.

Several studies indicate that schizophrenics who are not receiving maintenance treatment with an antipsychotic drug following an acute episode are at much greater risk of experiencing a relapse, according to Dixon. Consequently, many schizophrenic patients continue taking antipsychotic medication for the rest of their lives. Some may be able to take very low doses except when symptoms are severe. Between 15 and 20 percent of schizophrenic patients experience a relapse in any one year despite continued medication, according to John Kane, M.D., of the Albert Einstein College of Medicine in the Bronx.

Although there are injectable forms of antipsychotics, patients usually take these drugs orally. There is insufficient evidence to know whether they are associated with birth defects. Because these drugs can be passed to a baby via breast milk, schizophrenic mothers are usually discouraged from breast-feeding.

Other Treatments

Because some patients receive only partial relief of their symptoms from antipsychotic medications, doctors may prescribe additional medications. Studies suggest the addition of anti-anxiety medications such as lorazepam (Ativen) or alprazolam (Xanax) helps about half of schizophrenics, according to James Thompson, M.D., of the University of Maryland in Baltimore. He noted that a smaller percentage of patients also appear to receive some benefit from lithium and carbamazepine, which are also used to treat manic depression. Some studies cited by Thompson also suggest that antidepressants such as fluvoxamine may help diminish the depression, emotional blunting, and inability to speak some schizophrenic patients experience. However, since no pharmaceutical companies have sought FDA approval for antipsychotic claims for these drugs, FDA has not evaluated whatever data support such claims and, consequently, has not approved their use for schizophrenics.

Shocking patients with electricity, called electroconvulsive therapy, one of the earliest treatments of schizophrenia, is rarely used today because the benefits have not been definitively shown.

Once antipsychotic medications have helped stem schizophrenia's symptoms, many patients find the addition of individual, family or group psychotherapy to be helpful. According to Jack Scott, M.D., of the Maryland Psychiatric Research Center in Baltimore, recent studies indicate that supportive reality-oriented therapy aimed at developing practical interpersonal skills is generally of more benefit to schizophrenics than more probing psychoanalytic or insight-oriented psychotherapy. Rehabilitation programs that emphasize job counseling and training, problem-solving and money management skills, use of public transportation, and social skills training are often essential.

Although there currently is no cure for schizophrenia, the present array of drugs available often can effectively control many of the disorder's symptoms and enable patients to lead more satisfactory lives. A review of the life histories of almost 2,000 patients diagnosed with schizophrenia suggests that one-quarter achieve full remission, half recover at least partially, and one-quarter require long-term care, according to NIMH. It is unknown whether better results might be garnered with the newer antipsychotic drugs now on the market.

With appropriate treatment, many schizophrenics have been able to turn their imaginary hells into less terrifying and more fertile grounds. Bayley, for example, has transformed many of his bizarre visions into oil paintings and musical compositions. He notes that much can be gained by "tapping into a mind experiencing the truly extraordinary." He also advocates greater compassion for schizophrenics. "It is often forgotten that there is a person behind the condition, with a fundamental need to be understood," he wrote.

About the Author

www.fda.gov
FDA is A United States government body that oversees medical devices, including contact lenses, intraocular lenses, excimer lasers and eyedrops. In the US, these products must be approved by the FDA before they can be marketed.